Cristina Sevillano-Collantes

Endocrinology, Diabetes and Metabolism · 2014–2016

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Cristina Sevillano-Collantes trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. List (in Endocrinology, Diabetes and Metabolism)

Papers from Cristina Sevillano-Collantes's perspective

Ordered by how strongly the researchers Cristina Sevillano-Collantes trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
  2. 10-year follow-up of intensive glucose control in type 2 diabetes. (New England Journal of Medicine)
  3. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. (Cochrane Database of Systematic Reviews)
  4. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (British medical journal)
  5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (New England Journal of Medicine)
  6. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (New England Journal of Medicine)
  7. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. (New England Journal of Medicine)
  8. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3… (The Lancet)
  9. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise (Diabetes, obesity and metabolism)
  10. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (Diabetes Care)

Their papers